{
  "id": 14028747,
  "title": "Aston Science’s AST-301 Secures FDA Fast Track as Gastric Cancer Phase 2 Results Near",
  "url": "https://urgent.news/2026/10/12/aston-sciences-ast-301-secures-fda-fast-track-as-gastric-cancer-phase",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T19:40:07.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=158032"
  },
  "original_language": "en",
  "account": null,
  "summary": "Aston Science, a cancer vaccine developer, has secured Fast Track designation from the FDA for its investigational HER2-targeted therapeutic vaccine AST-301. This designation, granted on October 12, aims to expedite the development of the vaccine for treating HER2-expressing gastric cancer. Aston Science has completed patient enrollment and dosing in its Phase 2 trial, with results expected in October. The designation, granted approximately four months after AST-301 received orphan drug status, highlights the global competitiveness of Korean companies in cancer therapeutic vaccine development.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}